NEW YORK, Oct. 3, 2014 /PRNewswire/ -- Faruqi &
Faruqi, LLP, a leading national securities law firm, reminds
investors in AcelRx Pharmaceuticals, Inc. ("AcelRx" or the
"Company") (NASDAQ: ACRX) of the December 1,
2014 deadline to seek the role of lead plaintiff in a
federal securities class action lawsuit filed against AcelRx and
certain executives.
A complaint has been filed in the United States District Court
for the Northern District of California on behalf of all persons who
purchased or otherwise acquired AcelRx common stock and/or call
options, or sold/wrote AcelRx put options between December 2, 2013 and September 25, 2014, inclusive (the "Class
Period").
The complaint alleges that the Company and its executives
violated federal securities laws with respect to its disclosures
concerning its business, operations, and prospects.
Specifically, the action alleges that during the Class Period,
AcelRx made false and/or misleading statements and/or failed to
disclose that (i) the designs in the Instructions for Use of the
Zalviso System ("Zalviso") did not adequately address the risk of
the inadvertent misplacement of tablets; and (ii) the Company did
not submit sufficient data to the FDA in order to support the shelf
life of the product.
On September 26, 2014, AcelRx
announced that the resubmission process for its Zalviso New Drug
Application would not be complete until the first quarter of 2015
at the earliest.
Following this news, the price of AcelRx stock declined by
$1.31, or over 19%, to close at
$5.41 on September 26, 2014.
Request more information now by clicking here:
www.faruqilaw.com/ACRX. There is no cost or obligation to
you.
Take Action
If you invested in AcelRx stock or options between December 2, 2013 and September 25, 2014 and would like to discuss your
legal rights, visit www.faruqilaw.com/ACRX. You can also
contact us by calling Richard
Gonnello toll free at 877-247-4292 or at 212-983-9330 or by
sending an e-mail to rgonnello@faruqilaw.com. Faruqi &
Faruqi, LLP also encourages anyone with information regarding
AcelRx's conduct to contact the firm, including whistleblowers,
former employees, shareholders and others.
Faruqi & Faruqi, LLP is a national law firm which represents
investors and individuals in class action litigation. The
firm is focused on providing exemplary legal services in complex
litigation in the areas of securities, shareholder, antitrust and
consumer litigation, throughout all phases of litigation. The
firm has an experienced trial team which has achieved significant
victories on behalf of the firm's clients. To keep track of the
latest securities litigation news, follow us on Twitter at
www.twitter.com/MergerActivity or on Facebook at
www.facebook.com/FaruqiLaw.
Attorney Advertising. The law firm responsible for this
advertisement is Faruqi & Faruqi, LLP
(www.faruqilaw.com). Prior results do not guarantee or
predict a similar outcome with respect to any future matter.
We welcome the opportunity to discuss your particular case.
All communications will be treated in a confidential
manner.
FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn: Richard Gonnello,
Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330
Logo -
http://photos.prnewswire.com/prnh/20120119/MM38856LOGO
SOURCE Faruqi & Faruqi, LLP